Thursday, December 3, 2015

Chelation is Much More Effective than New Drug to Prevent CV Death for Diabetics

The new drug, empaliflozin, reduces the risk for future cardiac events, including premature death by 14% when added to conventional care.  This was in the front-page article of Family Practice News in October.  However, the TACT study of chelation produced a reduction of the same end points by about 50%.  Chelation also reduces the toxic metal load for patients, which might lessen the risk of cancer and other diseases.  If you are a diabetic, or even a pre-diabetic, I urge you to consider chelation.  Without chelation, having diabetes shortens the lifespan by 5-7 years.  Nothing works better.

See Family Practice News, October 15, 2015, p. 1.

No comments: